Signals+ October 2022

Photo of Amena Alrabeea in front of a waterfall

Member Highlight: Meet Amenah Alrabeea, Ph.D.

June 2, 2025

My research focuses on understanding how cytokine signaling, particularly IL-6, influences disease progression and drug resistance. I’m in the process of setting up my lab at Kuwait University, where aim to study the differences between classical and trans-signaling pathways of IL-6, and how they activate cells in distinct ways. Ultimately, [READ MORE]

Suraj Gupta, Birla Institute of Technology and Science, Pilani – Hyderabad Campus

June 2, 2025

Mr. Suraj Gupta is a fourth-year PhD Research Scholar at the Department of Pharmacy, BITS Pilani Hyderabad Campus, India, working under the supervision of Professor Sajeli Begum. His research involves the development of novel small-molecule cytokine inhibitors. A passionate medicinal chemistry enthusiast, his journey began during his B.Pharm and M.Pharm [READ MORE]

Clinical Trials, contributed by Howard A. Young

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

June 1, 2025

ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients [READ MORE]

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

June 1, 2025

ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) [READ MORE]

Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

June 1, 2025

ClinicalTrials.gov ID NCT06586710 Sponsor Meyer Children’s Hospital IRCCS Information provided by Carmela Errichiello, Meyer Children’s Hospital IRCCS (Responsible Party) Brief Summary Pediatric SLE includes monogenic forms, some of which involve the interferon type I (IFN-I) pathway. The IFN-I pathway is renally active in adult SLE and correlates with the extent [READ MORE]

Biweekly newsletter of the International Cytokine & Interferon Society

Signals+ Editors: Daniella Schwartz & Di Yu (Editors in Chief), Saurabh Chattopadhyay, Zhian Chen, Mohamed Saad & Maialen Sebastian-delaCruz

Cytokines 2025 is Coming! Visit the website often for updates.

Share this:

Cytokines 2025 is Coming! Visit the website often for updates.